Top

Published in:

01-11-2015 | Editorial

Not only for the risk of bone fracture

Author: Masafumi Fukagawa

Published in: Journal of Bone and Mineral Metabolism | Issue 6/2015

Excerpt

A higher incidence of bone fractures has been well recognized among patients with chronic kidney disease (CKD), especially in those on dialysis therapy [1]. Nevertheless, assessment of fracture risk in CKD patients has not been fully established yet. Although secondary hyperparathyroidism is the most frequent abnormality of mineral metabolism in CKD patients [2, 3], it is often difficult to evaluate bone turnover by the parathyroid hormone (PTH) level even in combination with serum bone metabolic markers, presumably because of the skeletal resistance to PTH caused by uremic toxins [4‐6]. Furthermore, significant correlations between the PTH level and fracture risk have not always been confirmed in CKD patients either, except for those with extremely high levels [7]. …

Wakasugi M, Kazama JJ, Taniguchi M, Wada A, Iseki K, Tsubakihara Y, Narita I (2013) Increased risk of hip fracture among Japanese hemodialysis patients. J Bone Min Metab 31:315–321CrossRef

Fukagawa M, Hamada Y, Nakanishi S, Tanaka M (2006) The kidney and bone metabolism: a nephrologist’s view. J Bone Min Metab 24:434–438CrossRef

Komaba H, Kakuta T, Fukagawa M (2011) Diseases of the parathyroid gland in chronic kidney disease. Clin Exp Nephrol 15:797–809CrossRefPubMed

Iwasaki-Ishizuka Y, Yamato H, Nii-Kono T, Fujieda A, Uchida M, Hosokawa A, Motojima M, Kurokawa K, Fukagawa M (2005) Down-regulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of chronic renal failure with low turnover bone. Nephrol Dial Transpl 20:1904–1911CrossRef

Nii-Kono T, Iwasaki Y, Yamato H, Fukagawa M (2007) Indoxyl sulfate induced skeletal resistance to PTH in osteoblastic cells. Kidney Int 71:738–743CrossRefPubMed

Tanaka H, Iwasaki Y, Yamato H, Mori Y, Komaba H, Watanabe H, Maruyama T, Fukagawa M (2013) P-Cresyl sulfate induces osteoblast dysfunction through activating JNK and p38 MAPK pathways. Bone 56:347–354CrossRefPubMed

Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gesham JL, Mason N, Prutz KG, Young EW, Pisoni (2006) Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the dialysis outcomes and practice patterns study. Kidney Int 70:1358–1366CrossRefPubMed

Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 76:S1–S130

Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T et al (2013) For the CKD-MBD guideline working group, Japanese Society for Dialysis Therapy: clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder (CKD-MBD). Ther Aphr Dial 17:247–288CrossRef

10.

Iimori S, Mori Y, Akita W, Kuyama T, Takada S, Asai T, Kuwahara M, Sasaki S, Tsukamoto Y (2012) Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fractures in CKD stage 5D patients—a single-center cohort study. Nephrol Dial Transpl 27:345–351CrossRef

11.

West SL, Lok CE, Langsetmo L, Chung AM, Szabo E, Pearce D, Fusaro M, Wald R, Weinstein J, Jamal SA (2015) Bone mineral density predicts fractures in chronic kidney disease. J Bone Miner Res. doi:10.1002/jbmr.2406 PubMed

12.

Kazama JJ, Matsuo K, Iwasaki Y, Fukagawa M (2015) Chronic kidney disease and bone metabolism. J Bone Miner Metab. doi:10.1007/s00774-014-0639-x

13.

Iwasaki Y, Kazama JJ, Yamato H, Shimoda H, Fukagawa M (2013) Accumulated uremic toxins attenuate elastic bone mechanical properties in rats with chronic kidney disease. Bone 57:477–483CrossRefPubMed

14.

Kazama JJ, Iwasaki Y, Fukagawa M (2013) Uremic osteoporosis. Kidney Int Supple 3:29–33CrossRef

15.

Yokoyama K, Taniguchi M, Fukagawa M (2013) A Japanese approach for CKD-MBD. Kidney Int Supple 3:34–39CrossRef

16.

Kanis JA, Johnell O, Oden A, Johansson H, McCloskey, (2008) FRAX and the assessment of fracture probability in men and women from UK. Osteoporos Int 19:385–397PubMedCentralCrossRefPubMed

17.

Fujiwara S, Nakamura T, Orimo H, Hosoi T, Gorai I, Oden A, Johansson H, Kanis JA (2008) Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int 19:429–435PubMedCentralCrossRefPubMed

18.

Jamal SA, West SL, Nickolas TL (2014) The clinical utility of FRAX to discriminate fracture status in men and women with chronic kidney disease. Osteoporos Int 25:71–76CrossRefPubMed

19.

Noylor KL, Leslie WD, Hodsman AB, Rush DN, Garg AX (2014) FRAX predicts fracture risk in the kidney transplant recipients. Transplant 97:940–945CrossRef

20.

Hayashi T, Joki N, Tanaka Y, Iwasaki M, Kubo S, Asakawa T, Matsukane A, Takahashi Y, Imamura Y, Hirahata K, Hase H (2015) The FRAX as a predictor of mortality in Japanese incident hemodialysis patients: an observational, follow-up study. J Bone Mineral Metab. doi:10.1007/s00774-014-0631-5

21.

Moe S, Drüeke T, Cunningham J et al (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 69:1945–1953CrossRefPubMed

22.

London GM, Marchais SJ, Guerin AP, Boutouyrie P, Metivier F, de Vernehoul MC (2008) Association of bone activity, calcium load, aortic stiffness, and calcification in ESRD. J Am Soc Nephrol 19:1827–1835PubMedCentralCrossRefPubMed

23.

Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429–435CrossRefPubMed

24.

Komaba H, Fukagawa M (2012) The role of FGF23 in CKD: with or without Klotho. Nature Rev Nephrol 8:484–490CrossRef

25.

Isakova T, Wahl P, Vargas GS, Gutierez OM, Scialla J et al (2011) Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79:1370–1378PubMedCentralCrossRefPubMed

26.

Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359:584–592PubMedCentralCrossRefPubMed

27.

Scialla JJ, Xie H, Rahman M, Anderson AH, Isakova T et al (2014) Chronic Renal Insufficiency Cohort (CRIC) study investigators fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol 25:349–360PubMedCentralCrossRefPubMed

28.

Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A et al (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest 121:4393–4408PubMedCentralCrossRefPubMed

29.

Andrukhova O, Slavic S, Smorodchenko A, Zeitz U, Shalhoub V, Lanske B, Pohl EE, Erben RG et al (2014) FGFwe regulates renal sodium handling and blood pressure. EMBO Mol Med 5:744–759

30.

Coe LM, Madathil SV, Casu C, Lanske B, Rivella S, Sitara D (2014) FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis. J Biol Chem 289:9795–9810PubMedCentralCrossRefPubMed

Title: Not only for the risk of bone fracture
Author: Masafumi Fukagawa
Publication date: 01-11-2015
Publisher: Springer Japan
Published in: Journal of Bone and Mineral Metabolism / Issue 6/2015
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI: https://doi.org/10.1007/s00774-015-0661-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2015

Bone-adiposity cross-talk: implications for pediatric obesity

Association between delivery at an advanced maternal age and osteoporosis in elderly Korean women

Comparison of expert and nonexpert physicians in the assessment of vertebral fractures using the semiquantitative method in Japan

List of reviewers 2014–2015

The impact of LRP5 polymorphism (rs556442) on calcium homeostasis, bone mineral density, and body composition in Iranian children

Number of osteoporotic sites as a modifying factor for bone mineral density

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials